Video

Dr. Mogal on the Role of Cytoreductive Surgery in Colorectal Peritoneal Carcinomatosis

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the role of cytoreductive surgery in colorectal peritoneal carcinomatosis.

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, physician, Seattle Cancer Care Alliance, associate professor, Department of Surgery, University of Washington (UW) School of Medicine, program director, Regional Cancer Therapies, UW Medicine, discusses the role of cytoreductive surgery in colorectal peritoneal carcinomatosis.

Although not all patients with colorectal peritoneal carcinomatosis are amenable for cytoreductive surgery, well-selected patients can derive a significant benefit from the operation, Mogal says. Findings from the phase 3 PRODIGE 7 trial (NCT00769405) showed that although adding hyperthermic intraperitoneal chemotherapy with oxaliplatin to cytoreductive surgery didn’t improve overall survival, complete cytoreductive surgery led to satisfactory survival outcomes when used as a curative intervention in patients with peritoneal carcinomatosis from colorectal cancer.

As such, cytoreductive surgery is preferred compared with systemic chemotherapy alone in well-selected patients, Mogal explains. Patient selection should incorporate a discussion with the patient within a well-established and experienced cancer center that utilizes multidisciplinary tumor boards, Mogal concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity